| P2093 | author name string | Zhiping Zhang | |
| | Tetsuro Sasada | |
| | Kunyu Yang | |
| | Songwei Tan | |
| | Anna Bershteyn | |
| | Tetsuya Ioji | |
| P2860 | cites work | Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma | Q24548019 |
| | Cancer immunotherapy: moving beyond current vaccines | Q24548229 |
| | Myeloid-derived suppressor cells: linking inflammation and cancer | Q24641811 |
| | Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 |
| | Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting | Q30444875 |
| | Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity | Q33562557 |
| | Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses | Q33652450 |
| | Evaluation of the levofloxacin release characters from a rabbit foldable capsular vitreous body | Q34139885 |
| | gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma | Q34188859 |
| | Progress on new vaccine strategies for the immunotherapy and prevention of cancer | Q34328457 |
| | Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines | Q34657707 |
| | Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax | Q35790603 |
| | Manipulating dendritic cell biology for the active immunotherapy of cancer | Q35825249 |
| | Immunity in response to particulate antigen-delivery systems | Q35961146 |
| | Dendritic cells as therapeutic vaccines against cancer | Q36085614 |
| | Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression | Q36347549 |
| | Translating innate immunity into immunological memory: implications for vaccine development | Q36404657 |
| | Regulatory T cells, tumour immunity and immunotherapy | Q36430144 |
| | Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines | Q36543806 |
| | Personalized peptide vaccines: a new therapeutic modality for cancer | Q36597682 |
| | Targeting dendritic cells with biomaterials: developing the next generation of vaccines | Q36627404 |
| | More than one reason to rethink the use of peptides in vaccine design | Q36808693 |
| | DC-based cancer vaccines | Q36809780 |
| | Solid lipid nanoparticles as a drug delivery system for peptides and proteins | Q36837529 |
| | Signaling defects in anti-tumor T cells | Q37063739 |
| | Multipeptide vaccination in cancer patients. | Q37547268 |
| | Directing dendritic cell immunotherapy towards successful cancer treatment | Q37754014 |
| | The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions | Q37772108 |
| | Dendritic cells and immunity against cancer. | Q37821074 |
| | Camouflage and sabotage: tumor escape from the immune system | Q37882478 |
| | Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery | Q39587181 |
| | Exuberated numbers of tumor-specific T cells result in tumor escape. | Q39986360 |
| | Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells | Q40015848 |
| | Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity | Q40062912 |
| | Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles | Q40327793 |
| | Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells | Q40351226 |
| | Polymer-supported lipid shells, onions, and flowers. | Q42554823 |
| | Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy | Q42595485 |
| | Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. | Q44412471 |
| | Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity | Q44906742 |
| | Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells | Q45214141 |
| | Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo | Q45309151 |
| | Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells | Q45413835 |
| | An improvement of double emulsion technique for preparing bovine serum albumin-loaded PLGA microspheres. | Q46411851 |
| | Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. | Q46732446 |
| P433 | issue | 5 | |
| P921 | main subject | nanoparticle | Q61231 |
| | immunotherapy | Q1427096 |
| | cancer immunotherapy | Q2012719 |
| P304 | page(s) | 635-647 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Nanomedicine | Q15817508 |
| P1476 | title | Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy | |
| P478 | volume | 9 | |